Biogen acquires HI-Bio for up to $1.8B, gaining access to felzartamab for rare immune conditions.

Biogen acquires Human Immunology Biosciences for up to $1.8B, including $1.15B upfront and $650M in potential milestone payments. The deal aims to expand Biogen's immunology pipeline and rare disease treatments, granting access to HI-Bio's lead asset, felzartamab, a potential first-in-class therapeutic for rare immune conditions. The acquisition is set to close in Q3, pending relevant approvals.